Tarsus Pharmaceuticals, Inc.
TARS
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.9B
$90.78
▲ +9.10%
P/E
-83.28
Mkt Cap
$3.9B
52-Wk Range
$48.20–$91.53
52-Week Range
$48.20 - $91.53
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 59.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized disease-targeted therapeutic development
- Advanced clinical-stage product pipeline
- Focused research in underserved medical conditions
- Proprietary lotilaner technology platform
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Moderate growth ahead
Expanding ophthalmology treatment market
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+52.2% over 3m
Quality
Excellent
High-growth business (105% revenue growth, 91% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TARS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 6, 2026
Reported EPS of -$0.43 vs -$0.19 consensus (-124.2% surprise). Revenue of $173.9M vs $169.7M expected (+2.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-124.2%
Revenue trend · last 8Q
—
+408%
+184%
+152%
+147%
+128%
+107%
+69%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$48.1M
$66.4M
$78.3M
$102.7M
$118.7M
$151.7M
$162.1M
$173.9M
Margins · last 8Q
Gross
93.0%
Operating
-11.4%
Profit
-10.7%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Aug 12, 2026
vs Industry
How TARS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related